{
    "id": 10514,
    "fullName": "NCOA4 - RET",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "NCOA4-RET (also referred to as RET/PTC3) results from the fusion of NCOA4 and RET, and leads to constitutive Ret kinase activity and transforming ability in culture (PMID: 9850089, PMID: 23150706, PMID: 30446652). NCOA4-RET fusions have been identified in papillary thyroid carcinoma, non-small cell lung cancre, and colorectaal cancer (PMID: 27849670, PMID: 23150706, PMID: 26078337).",
            "references": [
                {
                    "id": 3440,
                    "pubMedId": 9850089,
                    "title": "The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/9850089"
                },
                {
                    "id": 3441,
                    "pubMedId": 23150706,
                    "title": "RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23150706"
                },
                {
                    "id": 11213,
                    "pubMedId": 27849670,
                    "title": "RET/PTC3 Rearrangement in Papillary Thyroid Carcinoma: Possible Marker of Tumor Progression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27849670"
                },
                {
                    "id": 3842,
                    "pubMedId": 26078337,
                    "title": "Identification and characterization of RET fusions in advanced colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26078337"
                },
                {
                    "id": 15326,
                    "pubMedId": 30446652,
                    "title": "RET rearrangements are actionable alterations in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30446652"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 8031,
        "geneSymbol": "NCOA4",
        "terms": [
            "NCOA4",
            "ARA70",
            "ELE1",
            "PTC3",
            "RFG"
        ]
    },
    "variant": "NCOA4 - RET",
    "createDate": "08/13/2015",
    "updateDate": "03/25/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 5979,
                "geneSymbol": "RET",
                "terms": [
                    "RET",
                    "CDHF12",
                    "CDHR16",
                    "HSCR1",
                    "MEN2A",
                    "MEN2B",
                    "MTC1",
                    "PTC",
                    "RET-ELE1"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 2729,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lenvima (lenvatinib) inhibited Ret phosphorylation in human thyroid cancer cells expressing NCOA4-RET in culture (PMID: 23856031).",
            "molecularProfile": {
                "id": 10515,
                "profileName": "NCOA4 - RET"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid gland cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3395,
                    "pubMedId": 23856031,
                    "title": "Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23856031"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21313,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells derived from a patient with colon cancer harboring NCOA4-RET did not respond to treatment with Ibrance (palbociclib) in culture, demonstrating cell viability levels similar to control treatment (PMID: 30210625).",
            "molecularProfile": {
                "id": 10515,
                "profileName": "NCOA4 - RET"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 12496,
                    "pubMedId": 30210625,
                    "title": "NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30210625"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5159,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and reduced proliferation of transformed cells expressing NCOA4-RET in culture (PMID: 26046350).",
            "molecularProfile": {
                "id": 10515,
                "profileName": "NCOA4 - RET"
            },
            "therapy": {
                "id": 3274,
                "therapyName": "ALW-II-41-27",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4887,
                    "pubMedId": 26046350,
                    "title": "Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26046350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21318,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DS-5010 (BOS172738) inhibited proliferation of colorectal cancer cells harboring NCOA4-RET in culture, and resulted in durable tumor regression in a patient-derived xenograft (PDX) model (Cancer Res 2019;79(13 Suppl):Abstract nr 2199).",
            "molecularProfile": {
                "id": 10515,
                "profileName": "NCOA4 - RET"
            },
            "therapy": {
                "id": 9591,
                "therapyName": "DS-5010",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18455,
                    "pubMedId": null,
                    "title": "BOS172738: A novel highly potent and selective RET kinase inhibitor in Phase 1 clinical development",
                    "url": "https://cancerres.aacrjournals.org/content/79/13_Supplement/2199"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16822,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) treatment resulted in 97% tumor growth inhibition in patient-derived xenograft (PDX) models of colorectal cancer harboring NCOA4-RET (PMID: 30038711).",
            "molecularProfile": {
                "id": 10515,
                "profileName": "NCOA4 - RET"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12497,
                    "pubMedId": 30038711,
                    "title": "RET fusions observed in lung and colorectal cancers are sensitive to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30038711"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21311,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells derived from a patient with colon cancer harboring NCOA4-RET did not respond to treatment with Cometriq (Cabometyx, cabozantinib) in culture, demonstrating cell viability levels similar to control treatment (PMID: 30210625).",
            "molecularProfile": {
                "id": 10515,
                "profileName": "NCOA4 - RET"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 12496,
                    "pubMedId": 30210625,
                    "title": "NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30210625"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3226,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing NCOA4-RET (also referred to as RET-PTC3) in culture (PMID: 23526464).",
            "molecularProfile": {
                "id": 10515,
                "profileName": "NCOA4 - RET"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 312,
                    "pubMedId": 23526464,
                    "title": "Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23526464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11242,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RXDX-105 (CEP-32496) inhibited tumor growth in a patient-derived xenograft (PDX) model of colorectal cancer harboring NCOA4-RET (PMID: 28011461).",
            "molecularProfile": {
                "id": 10515,
                "profileName": "NCOA4 - RET"
            },
            "therapy": {
                "id": 1002,
                "therapyName": "RXDX-105",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9178,
                    "pubMedId": 28011461,
                    "title": "Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28011461"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21312,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells derived from a patient with colon cancer harboring NCOA4-RET did not respond to treatment with Nexavar (sorafenib) in culture, demonstrating cell viability levels similar to control treatment (PMID: 30210625).",
            "molecularProfile": {
                "id": 10515,
                "profileName": "NCOA4 - RET"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 12496,
                    "pubMedId": 30210625,
                    "title": "NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30210625"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21314,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells derived from a patient with colon cancer harboring NCOA4-RET were sensitive to treatment with Caprelsa (vandetanib) in culture, demonstrating decreased cell viability and inhibition of Akt and Erk phosphorylation (PMID: 30210625).",
            "molecularProfile": {
                "id": 10515,
                "profileName": "NCOA4 - RET"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12496,
                    "pubMedId": 30210625,
                    "title": "NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30210625"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9634,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, two patient with salivary duct carcinoma positive for AR and harboring NCOA4-RET demonstrated clinical efficacy when treated with Cometriq (Cabometyx, cabozantinib (PMID: 27334835).",
            "molecularProfile": {
                "id": 26940,
                "profileName": "NCOA4 - RET AR pos"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 50904,
                "name": "salivary gland carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7355,
                    "pubMedId": 27334835,
                    "title": "Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27334835"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15138,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a patient with lung adenocarcinoma harboring EGFR L858R and an acquired resistance mutation NCOA4-RET demonstrated stable disease for 7 months on Cometriq (Cabometyx, cabozantinib) in combination with Gilotrif (afatinib), whose disease progressed after 20 months of stable disease with Gilotrif (afatinib) alone (PMID: 29883838).",
            "molecularProfile": {
                "id": 30775,
                "profileName": "NCOA4 - RET EGFR L858R"
            },
            "therapy": {
                "id": 7420,
                "therapyName": "Afatinib + Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12672,
                    "pubMedId": 29883838,
                    "title": "Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29883838"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15130,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a patient with non-small cell lung cancer initially responded to Gilotrif (afatinib) treatment with a stable disease of 20 months, EGFR L858R and NCOA4-RET were identified in post-progression tumor samples (PMID: 29883838).",
            "molecularProfile": {
                "id": 30775,
                "profileName": "NCOA4 - RET EGFR L858R"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12672,
                    "pubMedId": 29883838,
                    "title": "Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29883838"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19902,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with an advanced solid tumor developed resistance to treatment with Tarceva (erlotinib) and was found via cell free DNA testing to harbor EGFR L858R and NCOA4-RET (PMID: 31300450).",
            "molecularProfile": {
                "id": 30775,
                "profileName": "NCOA4 - RET EGFR L858R"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17588,
                    "pubMedId": 31300450,
                    "title": "Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31300450"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15829,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with non-small cell lung carcinoma harboring an EGFR exon 19 deletion and an NCOA4-RET fusion had tumor shrinkage of 78% at 8-weeks and a response lasting more than 3.5 months, when treated with Tagrisso (osimertinib) and BLU-667, in combination (PMID: 30257958).",
            "molecularProfile": {
                "id": 31250,
                "profileName": "NCOA4 - RET EGFR exon 19 del"
            },
            "therapy": {
                "id": 7752,
                "therapyName": "BLU-667 + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12495,
                    "pubMedId": 30257958,
                    "title": "Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30257958"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 10515,
            "profileName": "NCOA4 - RET",
            "profileTreatmentApproaches": [
                {
                    "id": 6455,
                    "name": "RET Inhibitor",
                    "profileName": "NCOA4 - RET"
                }
            ]
        },
        {
            "id": 26940,
            "profileName": "NCOA4 - RET AR pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30775,
            "profileName": "NCOA4 - RET EGFR L858R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31250,
            "profileName": "NCOA4 - RET EGFR exon 19 del",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}